Pfizer (PFE) shares have been inching upward recently, sparking some fresh attention from investors looking to understand ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

Pfizer's revenue has stabilized, and a recent drug pricing deal with the US government reduces political uncertainty. Find ...

Pfizer (PFE) closed at $25.24 in the latest trading session, marking a -1.71% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.28% for the day. Elsewhere, the ...

Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.

Pfizer (PFE) has seen its stock price move gradually higher over the past week, rising nearly 15% in that period. Investors seem interested in the company’s recent performance and underlying ...

Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the ...

By stepping out as the first biopharma to win a three-year exemption from President Donald Trump’s earlier-announced plans for 100% tariffs, in return for agreeing to manufacture more of its drugs in ...

In the latest trading session, Pfizer (PFE) closed at $24.83, marking a +1.04% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.85%. Elsewhere, the Dow saw an upswing of ...

Obesity is a growing problem that now has effective treatments. Pfizer has been eager to develop a strong position in this area. This acquisition gives Pfizer a viable obesity drug candidate. Pfizer's ...

QSM Asset Management added 276,899 shares of Pfizer for an estimated $6.8 million in the third quarter. After the transaction ...